DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Aubrey Capital Management Ltd

Aubrey Capital Management Ltd lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,860 shares of the medical device company’s stock after selling 600 shares during the quarter. DexCom makes up approximately 1.5% of Aubrey Capital Management Ltd’s portfolio, making the stock its 15th biggest position. Aubrey Capital Management Ltd’s holdings in DexCom were worth $3,582,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stableford Capital II LLC lifted its stake in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares during the last quarter. Valley National Advisers Inc. lifted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. FORVIS Wealth Advisors LLC lifted its stake in DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after buying an additional 110 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after buying an additional 115 shares during the last quarter. Finally, HM Payson & Co. lifted its stake in DexCom by 8.5% in the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after buying an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 189,375 shares of company stock valued at $25,530,859. Insiders own 0.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Canaccord Genuity Group upped their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Raymond James upped their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Price Performance

DexCom stock traded down $13.67 during trading hours on Friday, hitting $124.34. The stock had a trading volume of 8,578,184 shares, compared to its average volume of 2,409,208. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The stock has a market capitalization of $49.24 billion, a price-to-earnings ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The stock’s fifty day moving average is $131.13 and its two-hundred day moving average is $118.30.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.38% and a net margin of 16.82%. As a group, analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.